Body fluid proteomics for biomarker discovery: Lessons from the past hold the key to success in the future

被引：194

作者：

Good, David M. ^{[2
]}

Thongboonkerd, Visith ^{[3
]}

Novak, Jan ^{[4
]}

Bascands, Jean-Loup ^{[5
,6
]}

Schanstra, Joost P. ^{[5
,6
]}

Coon, Joshua J. ^{[2
,7
]}

Dominiczak, Anna ^{[8
]}

Mischak, Harald ^{[1
]}

机构：

[1] Mosaiques Diagnost GmbH, Hannover, Germany

[2] Univ Wisconsin, Dept Chem, Madison, WI 53706 USA

[3] Mahidol Univ, Fac Med, Siriraj Hosp, Off Res & Dev,Med Mol Biol Unit, Bangkok 10700, Thailand

[4] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA

[5] INSERM, U858, I2MR, Dept Renal & Cardiac Remodelling,Team 5, F-31432 Toulouse 4, France

[6] Univ Toulouse 3, Inst Med Mol Rangueil, F-31000 Toulouse, France

[7] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA

[8] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland

来源：

JOURNAL OF PROTEOME RESEARCH | 2007年 / 6卷 / 12期

关键词：

biomarker; mass spectrometry; blood; urine; validation; diagnosis; prognosis;

D O I：

10.1021/pr070529w

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Sparked by the article from Lescuyer and colleagues in a recent issue, we aim here to further encourage interest in and discussion of clinically relevant biomarker research. We express our view on proteomics for biomarker discovery by addressing multiple relevant issues, including the inherent differences between biological fluids (and how these differences affect current analytical approaches) and experimental design to maximize the efficiency of moving from the bench to the bedside. Herein, we also include suggestions for definition of the term "biomarker", based on the use of a set of universal characterization/validation requirements, and illustrate several recent examples of successful transitions of benchtop proteomic studies work to clinical practice.

引用

页码：4549 / 4555

页数：7

共 55 条

[1] ABDI H., 2007, BONFERRONI SIDAK COR
[2] Imaging mass spectrometry at cellular length scales
Altelaar, A. F. Maarten
Luxembourg, Stefan L.
McDonnell, Liam A.
Piersma, Sander R.
Heeren, Ron M. A.
[J]. NATURE PROTOCOLS, 2007, 2 (05) : 1185 - 1196
[3] The human plasma proteome - History, character, and diagnostic prospects
Anderson, NL
Anderson, NG
[J]. MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (11) : 845 - 867
[4] Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA)
Anderson, NL
Anderson, NG
Haines, LR
Hardie, DB
Olafson, RW
Pearson, TW
[J]. JOURNAL OF PROTEOME RESEARCH, 2004, 3 (02) : 235 - 244
[5] Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients
Cicenas, J
Urban, P
Küng, W
Vuaroqueaux, V
Labuhn, M
Wight, E
Eppenberger, U
Eppenberger-Castori, S
[J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (05) : 636 - 645
[6] Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2
Cicenas, J
Urban, P
Vuaroqueaux, V
Labuhn, M
Küng, W
Wight, E
Mayhew, M
Eppenberger, U
Eppenberger-Castori, S
[J]. BREAST CANCER RESEARCH, 2005, 7 (04) : R394 - R401
[7] EFFLUX OF RADIOLABELED POLYETHYLENE GLYCOLS AND ALBUMIN FROM RAT-BRAIN
CSERR, HF
COOPER, DN
SURI, PK
PATLAK, CS
[J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1981, 240 (04): : F319 - F328
[8] Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis
Decramer, S
Wittke, S
Mischak, H
Zürbig, P
Walden, M
Bouissou, F
Bascands, JL
Schanstra, JP
[J]. NATURE MEDICINE, 2006, 12 (04) : 398 - 400
[9] Non-invasive markers of ureteropelvic junction obstruction
Decramer, Stephane
Bascands, Jean-Loup
Schanstra, Joost P.
[J]. WORLD JOURNAL OF UROLOGY, 2007, 25 (05) : 457 - 465
[10] deVera Imelda E, 2006, Clin Adv Hematol Oncol, V4, P541

← 1 2 3 4 5 6 →